Sosei Heptares
Sosei Heptares doses first patient in trial for inflammatory bowel disease treatment
March 21, 2024Research and Development Gastrointestinal tract, Sosei Heptares, clinical trial, inflammatory bowel disease, phase 1 trial
Sosei Heptares has announced that it has dosed the first patient in its phase 1 trial assessing a novel EP4 …
Neurocrine Biosciences begins phase 1 study assessing NBI-1117570 in healthy adults
September 12, 2023Research and Development Neurocrine Biosciences, Neurology, Sosei Heptares, clinical trial
Sosei Heptares has announced that its partner, Neurocrine Biosciences, has initiated its phase 1 first-in-human clinical trial to assess the …
Sosei Heptares and Cancer Research UK announce first patient dosed in phase 1/2a trial
August 10, 2023Research and Development Cancer Research UK, Oncology, Sosei Heptares, clinical trial, immunology
Sosei Heptares and Cancer Research UK have announced that the first patient has been dosed in their phase 1/2a clinical …
Sosei Heptares announces first subject dosed in phase 1 trial for schizophrenia therapy
July 3, 2023Research and Development HTL'149, Neurology, Sosei Heptares, clinical trial, schizophrenia
Sosei Heptares has announced that it has dosed its first patient in its phase 1 trial evaluating HTL0048149 (HTL’149), a …
Sosei Heptares and Metrion Biosciences to collaborate on structure-based drug discovery approaches to ion channels
February 1, 2021Sales and Marketing Sosei Heptares
Sosei Heptares has announced it will collaborate with Metrion Biosciences, a specialist ion channel CRO and drug discovery company, to …
Sosei Heptares and PharmEnable collaborate on neurological drug research
January 12, 2021Manufacturing and Production PharmEnable, Sosei Heptares
Sosei Group Corporation and PharmEnable, a UK drug discovery company, have joined forces to apply their respective technologies to drive …
Sosei Heptares to regain rights to muscarinic agonist programmes
January 5, 2021Manufacturing and Production Sosei Heptares
Biopharmaceutical group Sosei Heptares has announced it is to regain the worldwide rights to its muscarinic agonist programmes, after they …
Takeda signs deal with Sosei Heptares worth $1.2 billion
August 6, 2019Manufacturing and Production GPCR, Sosei Heptares, Takeda, pharma, sosei
Takeda has entered into a partnership with Sosei Heptares to develop drugs that modulate G protein-coupled receptor (GPCR) targets. The …
Latest content
Santen joins inaugural Global Summit for Eye Health as partner
